|
Women's Interagency HIV Study (WIHS) Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Women's Interagency HIV Study (WIHS) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Women's Interagency HIV Study (WIHS) Clinical research trials and Women's Interagency HIV Study (WIHS) healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Women's Interagency HIV Study (WIHS). Women's Interagency HIV Study (WIHS) Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Women's Interagency HIV Study (WIHS) clinical trial. Participants typically obtain the most effective healthcare available for their Women's Interagency HIV Study (WIHS) condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "W" Clinical Trials Conditions > Women's Interagency HIV Study (WIHS)  Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The Women’s Interagency HIV Study (WIHS), a multicenter, prospective study, was established in August 1993 to carry out comprehensive investigations of the impact of HIV infection and its clinical, laboratory, and psychosocial effects in women. The purpose of this study is to collect and evaluate these data from HIV infected and at-risk women to better understand and provide support for women whom are currently HIV infected or who are at risk for HIV infection.
Details: HIV in women is increasing worldwide, with women comprising approximately 14% of the total adult and adolescent AIDS cases, the highest proportion yet reported. The impact of AIDS is particularly severe in minority populations; among women, African Americans, and Hispanics combined now represent the majority of AIDS cases (76%) in the United States. AIDS is now the third leading cause of death for women aged 25 to 44 (after cancer and cardiovascular disease) and is the leading cause of death of African American women in this age group. Studies of HIV and AIDS in women can play a unique role in testing new biological or socio-behavioral hypotheses at the population level and in linking basic science findings and laboratory methods to well-defined populations and communities. Research areas that are likely to draw more attention in the near future will include the study of pathogenicity and transmissibility of different HIV subtypes or recombinant forms and their interaction with variably susceptible individuals; the change in the scope of HIV natural history studies in the era of combination antiretroviral therapy; and the contribution of such studies to the design of a wide spectrum of prevention modalities (e.g., prevention of HIV and prevention of opportunistic infections). In addition, studies of natural history of HIV-related malignancies and active surveillance of malignancies in HIV infected and high-risk uninfected women may lead to new screening and prevention modalities in high-risk populations of women. Participants will have study visits every 6 months. Questionnaires regarding sexual behavior, health care utilization, medical and obstetric/gynecological history, psychosocial factors, and sociodemographics will be completed by participants. Physical, gynecological, and lipodystrophy examinations will also be conducted at each visit, and current medication regimen will be noted. Blood and other bodily fluid samples will be collected and registered in both local and national repositories of the WIHS in conjunction with NIAID.
Eligibility:
Study Type: Observational, Natural History, Longitudinal, Defined Population, Prospective Study
Minimum Age/Maximum Age: 13 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - HIV infected or uninfected and at high risk for HIV - Willing to have blood drawn - Give consent to have their specimens stored in the WIHS national repository - Willing to be retested for HIV infection for this study; if hardcopy documentation of a positive result from both an HIV ELISA test and a confirmatory Western blot are available, blood need not be drawn and women need not agree to be retested for HIV - Able to complete study visit interviews in English or Spanish - Able to travel to and from site clinic and participate in study visits as an outpatient - Have consent of parent or guardian if under 18; patients must be at least 18 years of age for enrollment at certain sites - Have documented highly active antiretroviral therapy (HAART) and pre-HAART CD4 counts and HIV RNA quantification, if appropriate (i.e., HIV-positive, self-reported HAART) Exclusion Criteria - Perinatally acquired HIV - Enrolled in the WIHS through another site - AIDS-related conditions; if a woman reports an AIDS-related condition during screening that sites can refute through medical records, the woman is still eligible for enrollment
Total Enrollment: 1078
Location and Contact Information:
Montefiore Medical Center
Bronx, New York, 10467
United States
Georgetown Univ Med Ctr
Washington D.C., District of Columbia, 20007
United States
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, 900331079
United States
University of California - San Francisco
San Francisco, California, 94122
United States
Chicago Consortium
Chicago, Illinois, 60612
United States
SUNY / Health Sciences Ctr at Brooklyn
Brooklyn, New York, 11203
United States
Additional Information:
Study ID Numbers: WIHS;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000797
Other Hiv Infections Studies:
1. Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
2. The Treatment of Tuberculosis in HIV-Infected Patients
3. A Study of Saquinavir Used Alone or in Combination with Other Anti-HIV Drugs in HIV-Infected Patients
4. The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children
5. A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given with Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other Bronx Clinical Trials
Women's Interagency HIV Study (WIHS)
|
|
|
|
|
|
|
|
